Aspyra voluntarily delists from Amex

Aspyra (Westlake Village, California) said that is has given notice to NYSE Amex of its decision to voluntarily delist its common stock from the Exchange and deregister its common stock under the Securities Exchange Act of 1934, as amended.

The Company's board of directors has elected to take this action for the following reasons:

• The nature and limited extent of the trading in the common stock, as well as the market value that the public markets are currently applying to the common stock.

• The direct and indirect costs associated with the preparation and filing of the company's periodic reports with the SEC.

• The fact that many other typical advantages of being a public company, including enhanced access to capital and the ability to use equity securities to acquire other businesses, are not currently sufficiently available to the company to an extent that would justify such costs.

The company has not made any arrangements to have its common stock listed on any other exchange or quoted in any other quotation medium.

Aspyra is a provider of Health Care Information Technology solutions and services to the healthcare industry.

First patient treated in Stabilimax trial

Applied Spine Technologies (Rocky Hill, Connecticut) reported the first patient surgery at Allegheny General Hospital (Pittsburgh), as part of Investigational Device Exemption clinical trial designed to evaluate the safety and effectiveness of the Stabilimax Dynamic Spine Stabilization System.

The Stabilimax Dynamic Spine Stabilization System is a posterior dynamic stabilization device designed to support an injured or degenerated spine without eliminating motion. The company says the Stabilimax is expected to offer numerous advantages over current spinal fixation products and even new artificial disc products including a much less invasive and less traumatic implant procedure, maintenance of spine motion and disc function, and the potential to prevent or slow adjacent-segment disc disease.